KIRKLAND, QC, May 31, 2016 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. KEYTRUDA is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status. "We are excited to share this announcement with
Watch this webinar on YouTube! View the slides on SlideShare! Pharma funding of patient groups: the building blocks of ethical and appropriate relationships from Canadian Cancer Survivor Network In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups. This webinar presented perspectives from subject matter experts from
Step 1: Make some coffee or tea Step 2: Invite colleagues and friends Step 3: Ask friends to donate Download your registration form and inspirational material below! Coffee Party Inspirations Hold a fancy hat party! Hold a used jewelery sale! Contest to guess the candies in the jar!
The Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health (CADTH) are pleased to jointly launch the recruitment process for a Health Technology Assessment (HTA) Patient Engagement Navigator to assist patient groups in understanding the HTA landscape and to provide patient groups with the support required to help optimize the
Watch the video on YouTube: View the slides on Slideshare: CADTH – Why it is important, and what now? from Canadian Cancer Survivor Network Webinar InformationThis webinar featured a round table discussion focusing on the 2016 CADTH Symposium and all the important take-aways for patients & survivors. Featured guests included: – Louise Binder, CCSN Health Policy Consultant, – Mona Forrest, CCSN Board Member, – Sabrina
TORONTO, May 4, 2016 /CNW/ – Dr. Janet Dancey, Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN) announced today the roll out of a new national campaign to raise awareness of cancer clinical trials in Canada ahead of International Clinical Trials Day on May 20. The Ask Me Campaign will be introduced at more than 60 cancer centres across Canada and include hospital staff wearing "Ask Me" buttons, as well as posters